Kallol Purkait

Dr. Kallol Purkait
Post-doctoral Fellow
Chimie ParisTech
PSL University
CNRS
Institute of Chemistry for Life and Health Sciences
Laboratory for Inorganic Chemical Biology
+33 1 44 27 56 04
kallol.purkait@chimieparistech.psl.eu

Kallol was born and grew up in the city of joy, Kolkata, India. He obtained his master’s degree in chemistry from the University of Calcutta, India. Then he joined the lab of Prof. Arindam Mukherjee for his doctoral research at IISER Kolkata, where he worked on development of metal complexes as anticancer agents. Now he has joined as a postdoctoral researcher in Prof. Gilles Gasser’s Lab, where he is working on novel photosensitizers to treat cancer. He is very passionate about playing badminton, football, volleyball and cricket. He likes travelling and hiking during his spare time.

Awards

2018: 2016: Springer Nature Reviews best poster awards, Symposium on Advanced Biological Inorganic Chemistry.

2015: Inter Indian Institute of Science Education and Research best poster awards, IISER Trivandrum.

Publications

[1] Cytotoxicity and reactivity of a redox active 1,4-quinone-pyrazole compound and its Ru(II)-p-cymene complex. Kallol Purkait and Arindam Mukherjee*. Inorg. Chim. Acta, 2020, 502, 1193612.

[2] A trans-dichloridoplatinum(II) complex of a monodentate nitrogen mustard: Synthesis, stability and cytotoxicity studies. Subhendu Karmakar, Saptarshi Chatterjee, Kallol Purkait, Arindam Mukherjee*. J. Inorg. Biochem., 2020, 204, 1109822.

[3] ATP7B binds Ruthenium(II) p-cymene half-sandwich complexes: Role of steric hindrance and Ru-I coordination in rescuing the sequestration. Kallol Purkait, Ruturaj, Arindam Mukherjee* and Arnab Gupta*. Inorg. Chem., 2019, 58, 22, 15659-15670.

[4] Synthesis, Structure, Stability, and Inhibition of Tubulin Polymerization by RuIIp‑cymene Complexes of Trimethoxyaniline Based Schiff Bases. Sourav Acharya, Moumita Maji, Ruturaj, Kallol Purkait, Arnab Gupta*, and Arindam Mukherjee*. Inorg. Chem., 2019, 58, 14, 9213-9224.

[5] Cytotoxic RuIIp-cymene complexes of an anthraimidazoledione: halide dependent solution stability, reactivity and resistance to hypoxia deactivation Amrita Sarkar, Sourav Acharya, Kumar Khushvant, Kallol Purkait and Arindam Mukherjee* Dalton Trans., 2019, 48, 7187-7197.

[6] Ruthenium(II) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies. Sudipta Bhattacharyya, Kallol Purkait and Arindam Mukherjee*. Dalton Trans., 2017, 46, 8539-8554.

[7] Anticancer activity of a chelating nitrogen mustard bearing tetrachloridoplatinum(IV) complex: better stability yet equipotent to the Pt(II) analogue. Subhendu Karmakar, Saptarshi Chatterjee, Kallol Purkait and Arindam Mukherjee*. Dalton Trans., 2016, 45, 11710-11722.

[8] Alteration of steric hindrance modulates glutathione resistance and cytotoxicity of three structurally related RuIIp-cymene complexes. Kallol Purkait, Saptarshi Chatterjee, Subhendu Karmakar and Arindam Mukherjee*. Dalton Trans., 2016, 45, 8541-8555.

[9] Anticancer activity of a cis-dichloridoplatinum(II) complex of a chelating nitrogen mustard: insight into unusual guanine binding mode and low deactivation by glutathione. Subhendu Karmakar, Kallol Purkait, Saptarshi Chatterjee and Arindam Mukherjee*. Dalton Trans., 2016, 45, 3599-3615.

[10] Nitric oxide release by N-(2-chloroethyl)-N-nitrosoureas: a rarely discussed mechanistic path towards their anticancer activity. Amrita Sarkar, Subhendu Karmakar, Sudipta Bhattacharyya, Kallol Purkait and Arindam Mukherjee*. RSC Adv., 2015, 5, 2137-2146.

[11] A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione. Kallol Purkait, Subhendu Karmakar, Sudipta Bhattacharyya, Saptarshi Chatterjee, Suman Kr Dey and Arindam Mukherjee*. Dalton Trans., 2015, 44, 5969-5973.

[12] A hydroquinone based palladium catalyst for room temperature nitro reduction in water. Alok Kumar, Kallol Purkait, Suman Kr. Dey, Amrita Sarkar and Arindam Mukherjee*. RSC Adv., 2014, 4, 35233-35237 (equal contribution)